Home
Search
BIO International Convention   |   June 3-6, 2024

Speakers & Presenters

All Speakers
By Count|Alphabetical
  • Show All
By Count|Alphabetical
  • Show All
By Count|Alphabetical
  • Show All
Company Type
  • Show All
Main Therapeutic Focus
  • Show All
Development Phase of Primary Product
  • Show All
Search Speakers
All Speakers
Filter by letter
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Results
Alvaro Amorrortu, MBA, MS
CHIEF EXECUTIVE OFFICER, MEDIPHAGE BIOCEUTICALS INC.
Mediphage Bioceuticals
Toronto, Ontario, Canada
Rachel Anatol, PhD
SVP, SCIENCE & REGULATORY AFFAIRS, BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)
Accelerated Approval Under Pressure: What’s At Stake and What Can Be Done?
Querida Anderson
EDITORIAL DIRECTOR AND BIOPHARMA EXPERT, FORMER MANAGING EDITOR, FIERCE PHARMA
Fireside Chat with James Healy, Managing Partner, Sofinnova Investments
Susan Angele
SENIOR ADVISOR, BOARD LEADERSHIP CENTER, KPMG
Planning for the Future: Building Inclusive Corporate Boards
Derek Ansel
EXECUTIVE DIRECTOR, THERAPEUTIC STRATEGY LEAD, RARE DISEASE (WORLDWIDE CLINICAL TRIALS)
Designing Decentralized Clinical Trials from a Patient Perspective
Jim Anthony
EXECUTIVE VICE PRESIDENT AND GLOBAL HEAD, PAREXEL BIOTECH
Tailored Regulatory and Access Strategies to Drive Cell and Gene Therapy Innovation and Value for Clinical Developers
James Appleby
CEO, THE GERONTOLOGICAL SOCIETY OF AMERICA
The Future of the Vaccine Safety Net: Ensuring Equity, Access, Innovation, and the Business of Vaccines
Placeholder Photo
Luana Aps
CEO, CO-FOUNDER, IMUNOTERA SOLUçõES TERAPêUTICAS LTDA
ImunoTera
Thomas Argall
DEPUTY DIRECTOR, FOREIGN INVESTMENT REVIEW, OFFICE OF GLOBAL INVESTMENT AND ECONOMIC SECURITY, U.S. DEPARTMENT OF DEFENSE
Biotech and National Security: Considerations for Receiving Foreign Investment and CFIUS
Daniel Arlow, PhD
CEO, ANSA BIOTECHNOLOGIES, INC.
Making the Dream of Synthetic Biology a Reality
Berkeley, California, United States